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Leptin is involved in the endocrine control of energy expenditure and body weight regulation. Previous studies emphasize a
relationship between hypoxic states and leptin concentrations. The aim of this study was to investigate the eﬀects of acute hypoxia
onleptinconcentrationsinhealthysubjects.Weexamined14healthymen.Hypoxicconditionswereinducedbydecreasingoxygen
saturation to 75% for 30 minutes. Plasma leptin concentrations were determined at baseline, after 3 hours of euglycemic clamping,
during hypoxia, and repeatedly the following 2.5 hours thereafter. Our results show an increase of plasma leptin concentrations
in the course of 6 hours of hyperinsulinemic-euglycemic clamping which may reﬂect diurnal rhythmicity. Notwithstanding, there
wasnodiﬀerencebetween levelsofleptininthehypoxicandthenormoxiccondition(P = .2).Sincewedidnotﬁndanysigniﬁcant
changes in leptin responses upon hypoxia, plasma leptin levels do not seem to be aﬀected by short hypoxic episodes of moderate
degree.
Copyright © 2009 Andre Schmoller et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Hypoxia is suggested to play an important role in the
pathogenesis of endocrine and metabolic dysregulation in
obesityandthemetabolicsyndrome[1].Wecouldpreviously
demonstrate, based on an experimental human in vivo
design established in our group, that 30 minutes of oxygen
desaturation to 75% are suﬃcient to induce features of the
metabolic syndrome such as glucose intolerance [2, 3]a n d
respective changes in sympathetic activation [2, 3], resting
energy expenditure [2, 3], and vascular endothelial growth
factor(VEGF)levels[4],ahormonewhichhasbeenassumed
to play a role in the pathogenesis of the metabolic syndrome
[5].
Another hormone centrally involved in body weight
regulation and thereby the development of the metabolic
syndrome is leptin [6]. Leptin is synthesized mainly, but
not exclusively, by white adipose tissue sending a feedback
signal to the brain about the amount of peripheral fat stor-
ages. The secretion of leptin underlies various inﬂuencing
factors. Recent literature indicates that circulating leptin
concentrations are possibly increased by hypoxic conditions
in humans, suggesting a link to the obstructive sleep apnea
syndrome (OSAS), a disease characterized by recurrent night
apneic periods, which is strongly associated with obesity [7].
Indeed,ascomparedtohealthycontrols,OSASpatientsshow
elevated leptin concentrations which return to normal after
elimination of night apneas by continuous positive airway
pressure (CPAP) therapy [8]. However, it remains unclear if
high leptin levels in these patients are related to hypoxia, to
hormonal interactions, or to the frequently increased body
mass in OSAS. Athigh altitude (3000–4000m), thatis, under
constant hypoxic conditions, increased [9, 10]a sw e l la s
decreased leptin concentrations [11]h a v eb e e nr e p o r t e di n
humans as compared to sea level. Potential confounders of
leptin secretion in this setting are physical strain, nutritional
diﬀerences, or physical stress upon ascension. Previous
studies using cell cultures [12–14] and animal models have2 International Journal of Endocrinology
provided [15] a contradicting evidence for an impact of
hypoxia on leptin concentrations.
In order to clarify if hypoxia aﬀects circulating leptin
concentrations in humans, we experimentally induced a
short hypoxic period as compared to normoxic condition
in healthy normal weight participants according to our
established study design which has been demonstrated to
induce clinically relevant changes in energy and hormone
metabolism [2, 3]. Oxygen saturation of 75%, as applied in
our study, corresponds to a physiological state at approxi-
mately an altitude of 3500–4000m. To control for common
biases known to inﬂuence leptin metabolism, we performed
our study at rest. Moreover, our group has previously shown
that the glucose metabolism is a main determinant of
leptin secretion [16, 17]. Each subject, therefore, underwent
an euglycemic glucose clamp procedure to ensure stable
circulating glucose and insulin concentrations throughout
the experiments to control for these inﬂuencing factors on
plasma leptin levels. Additionally, sympathetic activation as
evaluated by circulating epinephrine and norepinephrine
concentrations was monitored.
2. Methods and Procedures
2.1. Subjects. Experiments were performed including 14
healthy men aged 20–25 years. Exclusion criteria were
overweight (body mass index (BMI) >25kg/m2), chronic
or acute illness (particularly respiratory diseases), alcohol
or drug abuse, smoking, competitive sports, exceptional
physical or mental stress, and current medication of any
kind. Each participant gave a written informed consent, and
the study was approved by the local ethics committee.
2.2. Experimental Design. Subjects participated in a hypoxic
and a normoxic session separated by an interval of at least 4
weeks.Hyperinsulinemic-euglycemicclampprocedureswere
performed during the entire experimental testing. A detailed
clamping procedure has been described previously [2, 17].
Subjects were blinded for conditions.
On the days of experimental testing, subjects reported to
the medical research unit at 11:00 h after an overnight fast
of at least 12 hours. After 3 hours of clamping, hypoxia was
induced for 30 minutes by decreasing oxygen saturation to
75%. On the normoxic control condition, oxygen saturation
was held at the physiological level of 98%. We assessed the
course of leptin concentrations at baseline and repeatedly 3
hours after induction of hypoxia according to leptin’s half
life in normal weight men of about 3 hours by punctional
determination [18]. During induction of hypoxia and also
during the normoxic control period, participants breathed
at normobaric conditions through a tightly ﬁtting face mask
connected to a Trajan 808 fresh gas supply (Draeger Medical
Technology, Luebeck, Germany), using a valveless high-ﬂow
system between 14 and 17l/min. Inspired oxygen fraction
(FiO2) was varied by adjusting oxygen and nitrogen. Oxygen
saturation was continuously measured by pulse oxymeter
and was decreased to 75% within approximately 5 minutes.
After 30 minutes, oxygen saturation was quickly normalized.
Catecholamine levels were monitored at baseline and every
7.5 minutes during hypoxia (versus control).
2.3. Assays. All blood samples were immediately centrifuged
and the supernatants stored at −24
◦C until assay. Leptin
concentrationsweremeasuredbyELISA(DiagnosticSystems
Laboratories, Sinsheim, Germany; interassay coeﬃcient of
variation (CV) 4.4%, intra-assay CV 3.8%). Serum insulin
was measured by radioimmunoassay (Pharmacia Insulin
RIA 100, Pharmacia Diagnostics, Uppsala, Sweden; inter-
assay coeﬃcient of variation (CV) <5.8%, intra-assay CV <
5.4%). Blood glucose concentrations were monitored at
5-minute intervals throughout the experiment (Glucose
Analyser, Beckman Coulter, Inc. Munich, Germany). High
pressure liquid chromatography was applied to measure
plasma epinephrine (intra-assay CV < 2.9%; inter-assay
CV < 4.2%) and norepinephrine levels (intra-assay CV <
2.6%; inter-assay CV < 3.9%, Chromosystems, Munich,
Germany).
2.4. Statistical Analysis. Values are presented as mean values
±SEM. Analyses of variance (ANOVA) for repeated mea-
surements, including the factors “session” (hypoxia versus
normoxia) and “time” (time points of data collection) were
implemented and corrected according to the Greenhouse-
Geisser procedure. The interaction eﬀect of these two factors
was termed “session by time.” The area under the curve
(AUC) was calculated from 6 hours leptin short-proﬁles
to determine overall diﬀerences in leptin secretion between
the two sessions. In addition, student’s paired t-tests were
performed to compare hormone concentrations at single
time points. A P-value <.05 was considered signiﬁcant.
3. Results
3.1. Oxygen Saturation, Serum Insulin, Plasma Glucose,
and Catecholamines. Upon induction of hypoxia, oxygen
saturation decreased over a period of about 5 minutes
and was held stable at a plateau of 74 ± 2%. Oxygen
saturation (corresponding to 35–41mmHg PaO2) during
the corresponding period under the normoxic condition
remained at a mean level of 98 ± 2%. Determination of
plasma glucose concentrations and serum insulin conﬁrmed
that respective blood levels remained constant after having
reached the equilibrium and did not diﬀer between hypoxic
and normoxic conditions throughout the study (Figure 1).
Also, as already published [3], norepinephrine concentra-
tions did not diﬀer signiﬁcantly between the two sessions
(P = .3) whereas epinephrine levels were signiﬁcantly
higher under the hypoxic condition as compared with the
control session (P<. 01). The glucose infusion rates were
signiﬁcantly lower during the hypoxic as compared to the
normoxic period [2].
3.2.PlasmaLeptinConcentrations. Figure 2showsthecourse
of leptin concentrations during normoxic and hypoxic
conditions under euglycemia. Overall, leptin levels increased
signiﬁcantly during hypoxia (P<. 001) and normoxia (P<International Journal of Endocrinology 3
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Figure 1: Mean (±SEM) blood glucose concentrations (a) and plasma insulin (b) in the hypoxic (white circles) and the control (black
circles) condition. Gray area marks the time of hypoxic/normoxic intervention. The time course describes the period before and after the
hypoxic intervention was initiated (Time point 0).
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Figure 2: Mean (±SEM) plasma leptin concentrations in the
hypoxic (white squares) and the control (black squares) condition.
Gray area marks the time of hypoxic/normoxic intervention. The
red label marks the point of time leptin has signiﬁcantly increased.
The time course describes the period before and after the hypoxic
intervention was initiated (Time point 0).
.001) in the overall time course of 6 hours of measurements.
There were no statistical diﬀerences in leptin levels between
hypoxic and normoxic conditions as revealed by ANOVA
for repeated measurements for the “session” eﬀect (P =
.269) and the interaction eﬀect (P = .638). Analyses of the
AUCs of leptin concentrations conﬁrmed that there was no
diﬀerence between the two conditions (P = .180). Paired
t-test comparison revealed that there were no diﬀerences
between the groups at baseline (P = .446). Similarly, after
having reached the euglycemic equilibrium, plasma leptin
concentrations showed no signiﬁcant diﬀerences between
conditions directly before the induction of hypoxia, during
the hypoxic period, and during the 2.5 hours period after
hypoxia in t-test comparison of single time points (P = .137
for all).
4. Discussion
Our results show that plasma leptin concentrations are
not aﬀected by acute hypoxia as compared to normoxic
control in healthy subjects at rest. In contrast, previous
studies showed an inverse correlation of serum leptin levels
to altitude [11, 19, 20], that is, when altitude increase
serum leptin levels drop. However the eﬀects of hypoxia
on circulating leptin concentrations are contradicting as
recently discussed in detail by Sierra-Johnson et al. [21–23].
The underlying cause why our results do not conﬁrm
previous data indicating an increasing eﬀect of hypoxia
on leptin levels deserves to be explained. One reasoning
may be based on hormonal inﬂuences. Norepinephrine and
epinephrine have been shown to inhibit leptin secretion [24–
26], whereas glucocorticoids, for example, dexamethasone,
stimulate leptin secretion in humans [27, 28]. So it may be
speculated that in our study a potential increase in leptin
concentrations upon hypoxia may be masked by suppressing
eﬀects of the risen epinephrine levels under this condition.
This mechanism, however, can only remain speculation
within the scope of an in vivo approach as applied here and
requires some conﬁrmation in further studies.
Our second ﬁnding was a signiﬁcant increase in leptin
concentrations in the course of the six hours of the
experimental procedure. This is in line with the ﬁnding
that circulating leptin concentrations display ultradian and
circadian rhythmicity with a nadir about noon and the early
afternoon, and peak levels during the night [29, 30]. The
increase in leptin concentrations starting prenoon and the
following 6 hours as reported here may reﬂect this diurnal
variation. Moreover, the increased leptin concentrations may
also be due to the standardized insulin infusion during
the clamp [16, 17, 31]. Since insulin has been shown
to elevate leptin concentrations [17, 32], we intended to
exclude this biasing factor by applying the hyperinsulinemic-
euglycemic clamp technique which adjusts constant insulin
concentrations during the experiments. Notwithstanding,4 International Journal of Endocrinology
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Figure 3: Mean (±SEM) norepinephrine concentrations (a) in the hypoxic (white bars) and the control (black bars) condition. Mean
(±SEM) epinephrine concentrations (b) in the hypoxic (white bars) and the control (black bars) condition. Epinephrine concentrations
have signiﬁcantly increased in the hypoxic condition.
thismethodmayhavecontributedtotheoverallriseinleptin
levels even though in all conditions equally.
One central question we intended to focus by our study
was if alterations in leptin concentrations in OSAS patients
could be assigned either to recurrent hypoxia or to the
known high BMI which is a frequently found feature in this
disease. Generally, leptin is produced by white adipose tissue
and downregulates food intake by inhibiting neuropeptide
Y synthesis and elevating alpha-melanocyte stimulating
hormone synthesis in the hypothalamus, a feedback mech-
anism signalling increased peripheral fat reserves to cerebral
appetite centers [33]. Indeed, it has been shown that serum
leptin levels are positively correlated with the BMI [33, 34].
Remarkably, some studies could demonstrate that OSAS
patients, however, display higher leptin levels than BMI-
matched obese and normal weight subjects [34, 35]. Since
Leptin is a physiological feedback signal to reduce appetite
and thereby should prevent the development of obesity,
the occurrence of overweight and elevated circulating leptin
concentrations, as seen in OSAS patients, deserves an
explanation.Therearetwopossiblemechanismsconceivable.
One possible explanation is a congenital leptin deﬁciency,
although this is a rarely seen defect [36]. The second avowal
could be a relative leptin resistance, due to the fact that leptin
seemstodownregulateitsownreceptors,sohighleptinlevels
could possibly reduce the number of leptin receptors and
generate a relative leptin resistance which in turn causes
obesity [37]. On the other hand, it was demonstrated that
the apnea-hypopnea index (AHI) correlates positively with
serum leptin concentrations in patients with OSAS but
not in the BMI-matched control group and there was a
signiﬁcant decrease of serum leptin levels in OSAS patients
upon treatment with CPAP therapy over six months despite
of stable BMI values [34, 38]. Therefore, we can speculate
that recurrent oxygen desaturations in OSAS patients may
play a major role in the regulation of leptin concentrations
disregarding the inﬂuence of obesity. Notwithstanding, our
data do not conﬁrm the hypothesis that elevated leptin con-
centrations in OSAS patients are caused by hypoxia either.
This negative result, however, may be based on our study
protocol which fundamentally diﬀers from the approach of
other investigations. Our subjects underwent only a single
moderate hypoxic episode of 30 minutes in length. This
hypoxic pattern diﬀers from previous studies according to
length, frequency, and degree of oxygen desaturation [8, 9,
11, 12]. Zaccaria et al., for example, studied male subjects
at high altitude with an observation period of 20 days [11].
Therefore, it remains to be carefully considered to what
extentourﬁndingscanbeassignedtothehypoxicconditions
as present in OSAS where severe hypoxic periods, displaying
distinctly lower oxygen saturation values than 75%, can be
observed [8]. So eventually our negative ﬁndings may simply
reﬂect an insuﬃcient duration and the extent of hypoxia to
aﬀect leptin secretion. Notwithstanding, our study design
has been established to induce clinically relevant changes
in other features of the metabolic syndrome [2, 3] and is
therefore an adequate approach to gain ﬁrst insight into
the eﬀects of acute hypoxia in this context in humans. In
addition, this is the ﬁrst study investigating the eﬀects of
acute hypoxia on leptin concentrations controlling for fun-
damental inﬂuencing factors in healthy men. According to
our data, plasma leptin levels seem to be unaﬀected by short
hypoxic episodes of moderate degree. Future studies are
desirable to further clarify the relationship between hypoxia
andleptinregulationinphysiologicalandpathophysiological
states.
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